AbbVie wins FDA nod for DECNUPAZ in rare blood cancer

BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes

Novo Nordisk to showcase late-stage pipeline & semaglutide expansion at ADA 2026

The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs

Cornerstone Robotics secures EU CE mark and Singapore HSA approval for Sentire Surgical System

Dual regulatory clearances for Sentire(R) Endoscopic surgical system strengthen the company’s expansion across Europe and Asia-Pacific in minimally invasive robotic surgery

China greenlights Boehringer Ingelheim’s HERNEXEOS for aggressive lung cancer

The decision clears the drug as a monotherapy for adults with unresectable, locally advanced or metastatic non-small cell lung cancer

AstraZeneca to showcase cancer pipeline push at ASCO 2026

Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies

Bristol Myers Squibb & Anthropic redraw biopharma with Claude-powered enterprise AI

BMS is moving beyond conversational AI into what it describes as “agentic” systems

Novo Nordisk unveils breakthrough MASH data as ‘silent’ liver disease threatens 250 million

Strand Life launches advanced proteomics capabilities

The next-generation proteomics platform powered by Olink™ Explore HT enables simultaneous analysis of thousands of proteins from a single sample

Edwards Lifesciences highlights 10-year data reinforcing durability of RESILIA tissue

Vyome secures exclusive license from Impetis for selective JAK inhibitor programs

The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments